Dermatology

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announced these new findings on RPT904 (JYB1904) in chronic spontaneous urticaria.

Investigators synthesized existing data on psychiatric comorbidities and outcomes related to quality of life in pediatric vitiligo.

Experts discuss how innovative treatments are revolutionizing atopic dermatitis care for children.

This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.

In this episode, sisters and dermatologists Mona and Neda Shahriari discuss mentorship, motherhood, and the meaning of sisterhood in medicine.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

In this segment of her EADV interview, Markowitz highlights 3-D imaging data from the DISCOVER study on dupilumab (Dupixent) and atopic dermatitis in skin of color.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

This EADV interview features a discussion of data from the DISCOVER study on the effects of dupilumab (Dupixent) on atopic dermatitis in skin of color.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

In this interview, additional information on roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis was highlighted.

This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.